Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
Guaifenesin
Johnson & Johnson (Ireland) Limited
R05CA03
Guaifenesin
Syrup in sachet
guaifenesin
Not marketed
2022-01-28
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT NIPENESIN 200 MG SYRUP IN SACHET guaifenesin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You or the adolescent must talk to a doctor if you or the adolescent do not feel better or if you feel worse after 5 days WHAT IS IN THIS LEAFLET: 1. Whatis and what it is used for. 2. What you need to know before you take this Lue koko asiakirja. 3. How to take . 4. Possible side effects. 5. How to store . 6. Contents of the pack and other information 1. WHAT IS AND WHAT IS IT USED FOR contains guaifenesin and is used to help relieve chesty coughs in adults and adolescents aged 12 years and over. help loosen mucus (phlegm) from the lungs and make it easier to cough up. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE THIS DO NOT TAKE - if you are allergic to guaifenesin or any of the other ingredients of this medicine (listed in section 6) WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking if you: have had a cough or if you feel worse for more than 5 days or your cough recurs or is accompanied by a fever, rash, or persistent headache. have a persistent cough that may be caused by asthma. have a cough which brings up a lot of mucus (phlegm). have severe liver or kidney problems. have epilepsy since the product contains alcohol (see contains ethanol, glucose, sucrose, sodium benzoate, sodium and propylene glycol). CHILDREN AND ADOLESCENTS This medici
Health Products Regulatory Authority 31 January 2022 CRN009WM8 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Guaifenesin 200 mg syrup in sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 ml sachet contains 200 mg guaifenesin Excipient(s) with known effect For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Syrup in sachet Clear yellow-brown coloured syrup. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Guaifenesin 200 mg syrup in sachet indicated for the symptomatic relief of productive cough in adults and adolescents of 12 years and above. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults andadolescents of12 years andabove:_ One 10ml sachet (200 mg guaifenesin) 4 times a day. Maximum daily dose: 4 sachets (800 mg guaifenesin) _Paediatric population _ The safety and efficacy of Guaifenesin 200 mg syrup in sachet in children under 12 years has not yet been established No data are available _ _ _Elderly:_ As per adults. _Hepatic/renalimpairment:_ Caution should be exercised in severe hepatic and severe renal impairment (see Section 5.2). If cough worsens or persists for more than 5 days, tends to recur, or is accompanied by a fever, rash, or persistent headache, a physician should be consulted. Method of administration: Oral route. Tear the sachet open and put the solution directly in the mouth. Health Products Regulatory Authority 31 January 2022 CRN009WM8 Page 2 of 5 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE This product should not be used for persistent or chronic cough, such as occurs with asthma, or where cough is accompanied by excessive secretions, unless directed by a physician. A persistent cough may be a sign of a serious condition. If cough worsens or persists for more than 5 days, tends to recur, or is accompanied by a fever, rash, or persistent headache, a physician should be consulted. Caution should be exercis Lue koko asiakirja